Biologics

The global spine biologics market is forecasted to grow at a 4.4 percent compound annual growth rate to exceed $2.6 billion by 2020, according to a Market Research Engine report.

Huntington, W. Va.-based Marshall Orthopaedics surgeon Chad Lavender, MD, is now performing anterior cruciate ligament repair procedures using a patient's bone marrow.

Adipose-derived autologous stem cell therapy may be used to successfully repair a meniscus injury, according to a study in the Journal of Medical Cases.

Here are five new biologic device launches or releases in 2018 so far:

NanoFUSE Biologics will attend the 2018 International Meeting on Advanced Spine Techniques in Los Angeles between July 11 and July 14.

Global spine service company SpineMark partnered with Regenexx Corp. to refer candidates for surgery at the company's centers for excellence.

NanoFUSE Biologics appointed Archie Yamada as vice president of product business development.

Connect Healthcare Collaboration will recommend Regenexx to its employer partners in order to offer alternatives to orthopedic surgery.

Zimmer Biomet, the former U.S. exclusive distributor for BoneSupport, cancelled a majority of its Cerament Bone Void Filler orders for a three month period starting in June.

The FDA awarded approval for a second indication of Medtronic's Kyphon HV-R Bone Cement.